StreetInsider.com News Articles

Form SCHEDULE 13G/A Neuphoria Therapeutics Filed by: Coastlands Capital LP

Tue, 28 Jul 2026 10:31:00 -0400

si-local-file:///var/storage/secattach/20260728/26824292.html

Form SCHEDULE 13G/A Neuphoria Therapeutics Filed by: Coastlands Capital LP

Tue, 28 Jul 2026 10:31:00 -0400

si-local-file:///var/storage/secattach/20260728/26824292.html

Form 8-K Neuphoria Therapeutics For: Jul 20

Fri, 24 Jul 2026 06:02:00 -0400

si-local-file:///var/storage/secattach/20260724/26809979.html

Form 8-K Neuphoria Therapeutics For: Jul 20

Fri, 24 Jul 2026 06:02:00 -0400

si-local-file:///var/storage/secattach/20260724/26809979.html

Form DEFA14A Neuphoria Therapeutics

Fri, 24 Jul 2026 06:02:00 -0400

si-local-file:///var/storage/secattach/20260724/26809984.html

Form DEFA14A Neuphoria Therapeutics

Fri, 24 Jul 2026 06:02:00 -0400

si-local-file:///var/storage/secattach/20260724/26809984.html

Scancell to acquire Neuphoria in all-share deal, pursue Nasdaq listing

Thu, 23 Jul 2026 06:12:27 -0400

Scancell Holdings plc and Neuphoria Therapeutics Inc. (Nasdaq: NEUP) have announced an all-share merger agreement in which Scancell will acquire Neuphoria, with the combined company planning to list on Nasdaq under the ticker "SCLT" while retaining its existing AIM listing.

Under the terms of the deal, existing Scancell shareholders would own approximately 85.5% of the combined company, with Neuphoria shareholders holding the remaining 14.5%, excluding the impact of new shares issued through financing. Neuphoria stockholders will also receive contingent value rights tied to potential future milestone payments from Neuphoria's partnered assets.

Alongside the merger, Scancell expects to secure up to $89 million

Scancell to acquire Neuphoria in all-share deal, pursue Nasdaq listing

Thu, 23 Jul 2026 06:12:27 -0400

Alongside the merger, Scancell expects to secure up to $89 million

Scancell to acquire Neuphoria in all-share deal, pursue Nasdaq listing

Thu, 23 Jul 2026 06:12:27 -0400

Alongside the merger, Scancell expects to secure up to $89 million

Scancell to acquire Neuphoria in all-share deal, pursue Nasdaq listing

Thu, 23 Jul 2026 06:12:27 -0400

Alongside the merger, Scancell expects to secure up to $89 million

Scancell to acquire Neuphoria in all-share deal, pursue Nasdaq listing

Thu, 23 Jul 2026 06:12:27 -0400

Alongside the merger, Scancell expects to secure up to $89 million

Scancell to acquire Neuphoria in all-share deal, pursue Nasdaq listing

Thu, 23 Jul 2026 06:12:27 -0400

Alongside the merger, Scancell expects to secure up to $89 million

Scancell to acquire Neuphoria in all-share deal, pursue Nasdaq listing

Thu, 23 Jul 2026 06:12:27 -0400

Alongside the merger, Scancell expects to secure up to $89 million

Scancell to acquire Neuphoria in all-share deal, pursue Nasdaq listing

Thu, 23 Jul 2026 06:12:27 -0400

Alongside the merger, Scancell expects to secure up to $89 million

Scancell and Neuphoria Therapeutics Announce Merger Agreement and Financing

Thu, 23 Jul 2026 06:11:00 -0400

All-share transaction creating a combined company to operate as Scancell advancing a pipeline of targeted, off-the-shelf, active immunotherapies
Combined company to be listed on Nasdaq, in addition to Scancell’s existing AIM listing
Agreed pro forma merger ownership split: existing Scancell shareholders to own 85.5 per cent. of the combined company, with Neuphoria existing shareholders owning 14.5 per cent.1
Financing to fund the global registrational Phase 3 trial for lead programme, iSCIB1+ active immunotherapy in advanced melanoma